Global Impotence Agents Market Growth 2025-2031

Publication ID:

LPI04255190

Publication Date:

April 23, 2025

Pages:

116

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Impotence Agents market size is predicted to grow from US$ 3803 million in 2025 to US$ 5691 million in 2031; it is expected to grow at a CAGR of 7.0% from 2025 to 2031.
Impotence agents are the type of agents that used to treat erectile dysfunction in males and enable to increase sexual intercourse. These agents generally increase vasodilation and blood flow to the male genital organ and cause an erection. It is becoming of great importance to the healthcare sector and is expected to expand in the coming times.
Rising burden of lifestyle diseases and growing prevalence of sedentary lifestyles have led to the expansion of the erectile dysfunction drugs market size. Leading to an increasing incidence of erectile dysfunction (ED) worldwide. According to the World Health Organization (WHO), erectile dysfunction affects approximately 15% of the male population each year and is expected to reach 320 million by 2025. Hence, increasing prevalence of diseases and rising demand for ED drugs is one of the key factors driving the market growth.
The 鈥淚mpotence Agents Industry Forecast鈥� looks at past sales and reviews total world Impotence Agents sales in 2024, providing a comprehensive analysis by region and market sector of projected Impotence Agents sales for 2025 through 2031. With Impotence Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Impotence Agents industry.
This Insight Report provides a comprehensive analysis of the global Impotence Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Impotence Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Impotence Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Impotence Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Impotence Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of Impotence Agents market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Oral Preparation
Injection
Other
Segmentation by Application:
Erectile Dysfunction
Premature Ejaculation
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer Inc
Bayer AG
Novartis AG
Hikma Pharmaceuticals plc
Aurobindo Pharma
VIVUS LLC.
Petros Pharmaceuticals, Inc.
Bristol-Myers Squibb Company
GSK PLC
Sanofi
Teva Pharmaceuticals Industries Ltd
Lilly
Adamed
Sun Pharmaceutical Industries, Ltd.
Auxilium Pharmaceuticals, Inc.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Impotence Agents market?
What factors are driving Impotence Agents market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Impotence Agents market opportunities vary by end market size?
How does Impotence Agents break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Impotence Agents Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Impotence Agents by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Impotence Agents by Country/Region, 2020, 2024 & 2031
2.2 Impotence Agents Segment by Type
2.2.1 Oral Preparation
2.2.2 Injection
2.2.3 Other
2.3 Impotence Agents Sales by Type
2.3.1 Global Impotence Agents Sales Market Share by Type (2020-2025)
2.3.2 Global Impotence Agents Revenue and Market Share by Type (2020-2025)
2.3.3 Global Impotence Agents Sale Price by Type (2020-2025)
2.4 Impotence Agents Segment by Application
2.4.1 Erectile Dysfunction
2.4.2 Premature Ejaculation
2.4.3 Other
2.5 Impotence Agents Sales by Application
2.5.1 Global Impotence Agents Sale Market Share by Application (2020-2025)
2.5.2 Global Impotence Agents Revenue and Market Share by Application (2020-2025)
2.5.3 Global Impotence Agents Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Impotence Agents Breakdown Data by Company
3.1.1 Global Impotence Agents Annual Sales by Company (2020-2025)
3.1.2 Global Impotence Agents Sales Market Share by Company (2020-2025)
3.2 Global Impotence Agents Annual Revenue by Company (2020-2025)
3.2.1 Global Impotence Agents Revenue by Company (2020-2025)
3.2.2 Global Impotence Agents Revenue Market Share by Company (2020-2025)
3.3 Global Impotence Agents Sale Price by Company
3.4 Key Manufacturers Impotence Agents Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Impotence Agents Product Location Distribution
3.4.2 Players Impotence Agents Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Impotence Agents by Geographic Region
4.1 World Historic Impotence Agents Market Size by Geographic Region (2020-2025)
4.1.1 Global Impotence Agents Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Impotence Agents Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Impotence Agents Market Size by Country/Region (2020-2025)
4.2.1 Global Impotence Agents Annual Sales by Country/Region (2020-2025)
4.2.2 Global Impotence Agents Annual Revenue by Country/Region (2020-2025)
4.3 Americas Impotence Agents Sales Growth
4.4 APAC Impotence Agents Sales Growth
4.5 Europe Impotence Agents Sales Growth
4.6 Middle East & Africa Impotence Agents Sales Growth
5 Americas
5.1 Americas Impotence Agents Sales by Country
5.1.1 Americas Impotence Agents Sales by Country (2020-2025)
5.1.2 Americas Impotence Agents Revenue by Country (2020-2025)
5.2 Americas Impotence Agents Sales by Type (2020-2025)
5.3 Americas Impotence Agents Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Impotence Agents Sales by Region
6.1.1 APAC Impotence Agents Sales by Region (2020-2025)
6.1.2 APAC Impotence Agents Revenue by Region (2020-2025)
6.2 APAC Impotence Agents Sales by Type (2020-2025)
6.3 APAC Impotence Agents Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Impotence Agents by Country
7.1.1 Europe Impotence Agents Sales by Country (2020-2025)
7.1.2 Europe Impotence Agents Revenue by Country (2020-2025)
7.2 Europe Impotence Agents Sales by Type (2020-2025)
7.3 Europe Impotence Agents Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Impotence Agents by Country
8.1.1 Middle East & Africa Impotence Agents Sales by Country (2020-2025)
8.1.2 Middle East & Africa Impotence Agents Revenue by Country (2020-2025)
8.2 Middle East & Africa Impotence Agents Sales by Type (2020-2025)
8.3 Middle East & Africa Impotence Agents Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Impotence Agents
10.3 Manufacturing Process Analysis of Impotence Agents
10.4 Industry Chain Structure of Impotence Agents
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Impotence Agents Distributors
11.3 Impotence Agents Customer
12 World Forecast Review for Impotence Agents by Geographic Region
12.1 Global Impotence Agents Market Size Forecast by Region
12.1.1 Global Impotence Agents Forecast by Region (2026-2031)
12.1.2 Global Impotence Agents Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Impotence Agents Forecast by Type (2026-2031)
12.7 Global Impotence Agents Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Pfizer Inc
13.1.1 Pfizer Inc Company Information
13.1.2 Pfizer Inc Impotence Agents Product Portfolios and Specifications
13.1.3 Pfizer Inc Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Pfizer Inc Main Business Overview
13.1.5 Pfizer Inc Latest Developments
13.2 Bayer AG
13.2.1 Bayer AG Company Information
13.2.2 Bayer AG Impotence Agents Product Portfolios and Specifications
13.2.3 Bayer AG Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Bayer AG Main Business Overview
13.2.5 Bayer AG Latest Developments
13.3 Novartis AG
13.3.1 Novartis AG Company Information
13.3.2 Novartis AG Impotence Agents Product Portfolios and Specifications
13.3.3 Novartis AG Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Novartis AG Main Business Overview
13.3.5 Novartis AG Latest Developments
13.4 Hikma Pharmaceuticals plc
13.4.1 Hikma Pharmaceuticals plc Company Information
13.4.2 Hikma Pharmaceuticals plc Impotence Agents Product Portfolios and Specifications
13.4.3 Hikma Pharmaceuticals plc Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Hikma Pharmaceuticals plc Main Business Overview
13.4.5 Hikma Pharmaceuticals plc Latest Developments
13.5 Aurobindo Pharma
13.5.1 Aurobindo Pharma Company Information
13.5.2 Aurobindo Pharma Impotence Agents Product Portfolios and Specifications
13.5.3 Aurobindo Pharma Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Aurobindo Pharma Main Business Overview
13.5.5 Aurobindo Pharma Latest Developments
13.6 VIVUS LLC.
13.6.1 VIVUS LLC. Company Information
13.6.2 VIVUS LLC. Impotence Agents Product Portfolios and Specifications
13.6.3 VIVUS LLC. Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 VIVUS LLC. Main Business Overview
13.6.5 VIVUS LLC. Latest Developments
13.7 Petros Pharmaceuticals, Inc.
13.7.1 Petros Pharmaceuticals, Inc. Company Information
13.7.2 Petros Pharmaceuticals, Inc. Impotence Agents Product Portfolios and Specifications
13.7.3 Petros Pharmaceuticals, Inc. Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Petros Pharmaceuticals, Inc. Main Business Overview
13.7.5 Petros Pharmaceuticals, Inc. Latest Developments
13.8 Bristol-Myers Squibb Company
13.8.1 Bristol-Myers Squibb Company Company Information
13.8.2 Bristol-Myers Squibb Company Impotence Agents Product Portfolios and Specifications
13.8.3 Bristol-Myers Squibb Company Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Bristol-Myers Squibb Company Main Business Overview
13.8.5 Bristol-Myers Squibb Company Latest Developments
13.9 GSK PLC
13.9.1 GSK PLC Company Information
13.9.2 GSK PLC Impotence Agents Product Portfolios and Specifications
13.9.3 GSK PLC Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 GSK PLC Main Business Overview
13.9.5 GSK PLC Latest Developments
13.10 Sanofi
13.10.1 Sanofi Company Information
13.10.2 Sanofi Impotence Agents Product Portfolios and Specifications
13.10.3 Sanofi Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Sanofi Main Business Overview
13.10.5 Sanofi Latest Developments
13.11 Teva Pharmaceuticals Industries Ltd
13.11.1 Teva Pharmaceuticals Industries Ltd Company Information
13.11.2 Teva Pharmaceuticals Industries Ltd Impotence Agents Product Portfolios and Specifications
13.11.3 Teva Pharmaceuticals Industries Ltd Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Teva Pharmaceuticals Industries Ltd Main Business Overview
13.11.5 Teva Pharmaceuticals Industries Ltd Latest Developments
13.12 Lilly
13.12.1 Lilly Company Information
13.12.2 Lilly Impotence Agents Product Portfolios and Specifications
13.12.3 Lilly Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Lilly Main Business Overview
13.12.5 Lilly Latest Developments
13.13 Adamed
13.13.1 Adamed Company Information
13.13.2 Adamed Impotence Agents Product Portfolios and Specifications
13.13.3 Adamed Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Adamed Main Business Overview
13.13.5 Adamed Latest Developments
13.14 Sun Pharmaceutical Industries, Ltd.
13.14.1 Sun Pharmaceutical Industries, Ltd. Company Information
13.14.2 Sun Pharmaceutical Industries, Ltd. Impotence Agents Product Portfolios and Specifications
13.14.3 Sun Pharmaceutical Industries, Ltd. Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Sun Pharmaceutical Industries, Ltd. Main Business Overview
13.14.5 Sun Pharmaceutical Industries, Ltd. Latest Developments
13.15 Auxilium Pharmaceuticals, Inc.
13.15.1 Auxilium Pharmaceuticals, Inc. Company Information
13.15.2 Auxilium Pharmaceuticals, Inc. Impotence Agents Product Portfolios and Specifications
13.15.3 Auxilium Pharmaceuticals, Inc. Impotence Agents Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Auxilium Pharmaceuticals, Inc. Main Business Overview
13.15.5 Auxilium Pharmaceuticals, Inc. Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂